The risk of multiple sclerosis (MS) is higher in women than in men. Besides, its incidence seems to be increasing, especially in women. Although little is known about the underlying causes for this increasing female preponderance, both genetic and environmental factors are probably involved. Investigating in depth the interactions in the female example may help understand broader gene-environment interactions that take place in this disease.
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In this issue of the Journal, two topical reviews focus on the role of gender and hormones in MS onset and course. 1, 2 Considering hormones, it is clear from both reviews that, at lower levels, oestrogens such as oestradiol may promote inflammation but, at higher levels, oestrogens such as the pregnancy hormone oestriol may induce a shift in the immune response, muting inflammation. Yet, these hormonal factors per se would not account for the increasing incidence in MS among women. Instead, a number of environmental factors and changes in lifestyle such as contraception, diet, obesity, smoking, sunlight exposure, vitamin D deficiency, higher age at first childbirth and fewer pregnancies could, interestingly, emerge as possible explanations for this increasing incidence. For this reason, puberty has been seen as a key period where metabolic factors, such as childhood diet, may lead to earlier menarche and obesity, thereby contributing to MS risk.
Regarding the disease course, both reviews emphasise that females are at higher risk for MS, but males are more likely to develop a progressive form of the disease and a more rapid accumulation of disability. Although the majority of these observations are based on data coming from large cohorts, with long followup times, these natural history studies have a number of limitations. [3] [4] [5] [6] For example, missing magnetic resonance imaging (MRI) data is common, which implies that important MRI-related covariates are frequently not taken into account when differences between men and women with MS are described. It is also surprising that these clinical differences between males and females have not been seen in the longitudinal MRI cohorts reported in the literature. 7, 8 It should be noted that, despite possible differences in clinical course, no gender differences have been found in terms of first-line disease-modifying treatment (DMT) efficacy, including beta-interferon and glatiramer acetate. [9] [10] [11] [12] Interestingly, Miller's review emphasises that when a pregnancy is contemplated by a patient and their partner, not only the effect of gestation on the course of MS has to be discussed but also many other aspects such as the impact of MS on fertility, risk of MS in offspring, risk to the child of a parent's MS medications before and during pregnancy, effect of MS on the ability to provide childcare and the associated socioeconomic burden to the family. 2 Cessation of treatment prior to conception may be especially complicated in patients with previous highly active relapsing-remitting MS, particularly with newer, more potent treatments. Miller et al. remind us that not only women but also men on MS treatment should be aware of the potential effects of DMT on fertility or future offspring. For example, teriflunomide is detected in semen and potential fathers should consider cholestyramine washout before conception. 2 There is a need for populationbased registries to address the impact of pregnancy and MS therapies during pregnancy on the long-term outcomes (for mother and child) of women with MS and their offspring.
As far as pregnancy is concerned, both reviews stress the dramatic decline in relapse risk in the last trimester of pregnancy, with a rebound in relapses (for up to 30% of women) noted in the first trimester postpartum. Of note, the observed association between breastfeeding and postpartum decrease in relapse risk may be confounded by the fact that mothers with more severe disease generally decide against breastfeeding. That is, because MS treatments may be detected in maternal milk, women with MS are generally recommended not to take such treatments while breastfeeding, and only those with a milder disease, who do not need DMT, would finally decide to breastfeed their child. 1, 2 Assisted reproductive techniques are becoming widely used and although definite recommendations are still lacking, they are probably associated with an increase in clinical and MRI activity. It is clear from both reviews that we still know very little on the impact of menopausal hormone changes on the course of MS. In addition, these hormonal changes per se may be confounded by age-related changes in MS disease activity and the presence of comorbidities.
As pointed out in these two topical reviews, the potential modulatory role for hormone-based therapies should be thoroughly explored.
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